Clinical Trial Update: Rhenium Re 188 P2045 in Patients With Lung Cancer Who Have Received or Refused to Receive Prior Chemotherapy [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial update for Rhenium Re-188 P2045 in patients with lung cancer, including non-small cell and small cell types, who have had prior chemotherapy or …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Carcinoma Non-small-cell Lung
• Carcinoma Small Cell
• Lung Neoplasms

Drugs mentioned

• Rhenium Re-188 P2045 (Rhenium Re-188 P2045)

Snippet

Sponsor: Andarix Pharmaceuticals | Conditions: Lung Neoplasms, Carcinoma, Non-Small-Cell Lung | Phase 1, Phase 2 | Status: UNKNOWN